Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
IMUNON Reports 2023 Financial Results and Provides Business Update
08:00am, Thursday, 28'th Mar 2024
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
08:30am, Monday, 25'th Mar 2024
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-developm
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
05:00pm, Thursday, 21'st Mar 2024
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac
IMUNON Files IND Application to Begin Human Testing of IMNN-101
08:00am, Wednesday, 13'th Mar 2024
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA
IMUNON Announces Leadership Change
05:00pm, Tuesday, 12'th Mar 2024
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-develop
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
08:00am, Thursday, 22'nd Feb 2024
Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage dr
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Monday, 11'th Dec 2023
Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases
Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript
06:29pm, Friday, 17'th Nov 2023
Imunon, Inc. (NASDAQ:IMNN ) Q3 2023 Earnings Call Transcript November 14, 2023 10:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Corinne Le Goff - President & Chief Executive Off
IMUNON's VP of R&D to Present at the Vaccines Summit-2023
09:00am, Tuesday, 14'th Nov 2023
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
08:00am, Tuesday, 14'th Nov 2023
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
08:30am, Tuesday, 07'th Nov 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc
IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress
08:30am, Monday, 23'rd Oct 2023
Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
08:30am, Tuesday, 05'th Sep 2023
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annu
